NBIX vs NERV · P/E 45, rev $1.77B vs P/E 2.2, $12.4M cap
Neurocrine Biosciences Inc (NBIX) versus Minerva Neurosciences Inc (NERV) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Minerva Neurosciences Inc (NERV) is a biotechnology company listed on US.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
NERV does not have a complete income-statement cache yet.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. NERV currently screens at market cap $12.4M and trailing P/E 2.2.
Not investment advice. Open the NBIX and NERV stock pages for the full models.
Not investment advice.